DAKO

News DAKO

• Agilent to Acquire Dako for $2.2 Billion

  Agilent Technologies Inc. and EQT, the Sweden-based private equity group,  announced the execution of a definitive agreement for Agilent to acquire Dako, the Denmark-based cancer diagnostic company. The $2.2 billion acquisition (on a debt-free basis) is the largest in Agilent’s history. “In the rapi more

• Dako Enters New Collaboration with Bristol-Myers Squibb on Pharmacodiagnostics

  Dako announced it has entered into a broad framework agreement with Bristol-Myers Squibb Company on the development of pharmacodiagnostic tests intended to identify patients more likely to benefit from treatment with investigational drug candidates under development by Bristol-Myers Squibb. The agre more

• Dako appoints new CFO

  As of May 9, 2011, Egil Mølsted Madsen takes over the position of Chief Financial Officer (CFO) of Dako A/S and Dako Denmark, a worldwide provider of cancer diagnostics solutions."Dako has just released its 2010 results. The best results ever in the company's history. However, our company holds even more

White papers DAKO

• Superiority of FuGENE® HD Transfection Reagent in Minimizing Non-Specific Cellular Interferon Responses
  

  Many viruses, including human cytomegalovirus (HCMV), encode for genes that can modulate or interfere with the ability of cells to mount an effective antiviral response to infection. Transfection of viral genes into cultures of mammalian cells is an important research tool to evaluate the function of viral gene products. We utilized this approach to identify viral genes involved in modulation of interferon (IFN)-mediated cell signaling pathways. more

Publications DAKO

• p53 protein accumulation and p53 gene mutation in colorectal cancer

  Comparison of immunohistochemical methods for detection of protein p53 accumulation and molecular techniques for analysis p53 gene mutation in colorectal cancer is presented. Thirty eight patients were included: all underwent surgery without preoperative treatment. Sex of patients, tumor localisatio more

Market studies DAKO

• Global In Vitro Diagnostics Market 2011-2015

  TechNavio's analysts forecast the Global In Vitro Diagnostics market to grow at a CAGR of 6.55 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing demand for biomarker-based tests worldwide. The Global In Vitro Diagnostics market has also be more

• Leading Anti-Cancer Drugs: World Market Prospects 2011-2021

  What will this decade hold for leading anti-cancer drugs and that therapeutic market? Our new report shows you anti-cancer drug revenue forecasts for 2011 to 2021. We provide research, data and opinions to benefit your work now. What revenues will cancer treatment markets generate from 2011 to 2021 more

Websites DAKO